Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma

Table 6 Univariate and multivariate analysis for overall survival

Prognostic factors	Univariate analysis			Multivariate analysis
	Hazard ratio	95%CI	P value	Hazard ratio	95%CI	P value
Gender (male)	0.968	0.387-2.419	0.945
Age (≥ 70 yr)	0.770	0.355-1.670	0.508
AFP (≥ 400 ng/mL)	2.662	1.181-6.001	0.018	2.548	1.070-6.068	0.035
BCLC (terminal)	7.022	2.442-20.19	< 0.001	9.809	2.589-37.17	< 0.001
Child-Pugh (≥ 7)	3.031	1.258-7.301	0.013	1.364	0.510-3.645	0.536
Diameter (≥ 30 mm)	0.654	0.285-1.500	0.316
Dose (≥ 30 Gy)	0.302	0.114-0.804	0.017	0.274	0.093-0.7541	0.012
Dose/fraction (≥ 8 Gy)	1.889	0.790-4.516	0.153
Lesion (extrahepatic)	1.789	0.665-4.817	0.250
Fiducial (+)	0.491	0.195-1.238	0.132	0.783	0.264-2.321	0.659
Sorafenib (+)	1.068	0.247-4.618	0.930

Cox proportional hazards model was used to evaluate the prognostic factors for overall survival. AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer.